NAUT (Nautilus Biotechnology) YoY EBITDA Growth: 7.32% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NAUT Nautilus Biotechnology Inc NAUT
22 GF Score
Price $1.02
! 2 Warning Signs
View Full Analysis

What is Nautilus Biotechnology YoY EBITDA Growth?

Nautilus Biotechnology NAUT +3.20% 22 YoY EBITDA Growth is 7.32% as of Jun. 2026. GuruFocus rates NAUT with a GF Score™ of 22/100. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Nautilus Biotechnology's YoY EBITDA Growth for the quarter that ended in Jun. 2026 was 7.32%.

Nautilus Biotechnology's EBITDA per Share for the three months ended in Jun. 2026 was $-0.11.

Nautilus Biotechnology YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Nautilus Biotechnology's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nautilus Biotechnology YoY EBITDA Growth Chart

Nautilus Biotechnology Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
YoY EBITDA Growth
Get a 7-Day Free Trial -422.22 14.36 -16.77 -6.03 20.07

Nautilus Biotechnology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.61 20.86 25.34 15.33 7.32
NAUT
22GF Score
Nautilus Biotechnology Inc NAUT
YoY EBITDA Growth is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nautilus Biotechnology YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Nautilus Biotechnology's YoY EBITDA Growth for the fiscal year that ended in Dec. 2025 is calculated as:

YoY EBITDA Growth (A: Dec. 2025 )
=(EBITDA per Share (A: Dec. 2025 )-EBITDA per Share (A: Dec. 2024 ))/ | EBITDA per Share (A: Dec. 2024 ) |
=(-0.478--0.598)/ | -0.598 |
=20.07 %

Nautilus Biotechnology's YoY EBITDA Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EBITDA Growth (Q: Jun. 2026 )
=(EBITDA per Share (Q: Jun. 2026 )-EBITDA per Share (Q: Jun. 2025 )) / | EBITDA per Share (Q: Jun. 2025 )) |
=(-0.114--0.123)/ | -0.123 |
=7.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 7.32% mean?
Nautilus Biotechnology (NAUT) has a YoY EBITDA Growth of 7.32% as of Jun. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Nautilus Biotechnology and its competitors.
Is Nautilus Biotechnology's YoY EBITDA Growth too high?
Nautilus Biotechnology's current YoY EBITDA Growth is 7.32%. Overall, Nautilus Biotechnology has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Nautilus Biotechnology's YoY EBITDA Growth compare to SEER and ONCY?
Nautilus Biotechnology's YoY EBITDA Growth of 7.32% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Biotechnology company?
A good YoY EBITDA Growth depends on the Biotechnology industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Nautilus Biotechnology and its competitors. Nautilus Biotechnology's current YoY EBITDA Growth is 7.32%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nautilus Biotechnology stock overvalued right now?
Nautilus Biotechnology (NAUT) has a current YoY EBITDA Growth of 7.32%. The current YoY EBITDA Growth is 7.32%. Nautilus Biotechnology's overall GF Score™ is 22/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Nautilus Biotechnology (NAUT), the current YoY EBITDA Growth is 7.32% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nautilus Biotechnology Business Description

Address 2701 Eastlake Avenue East, Seattle, WA, USA, 98102
Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. The Company transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its products includes: Proteome Analysis System, Reagent Kits, Software and analysis.
22GF Score

Get the complete analysis for NAUT

YoY EBITDA Growth is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price